References
1. U.S. Food and Drug Administration, Center for Biologics Evaluation and
Research. Important Safety Information on Interference With Blood Glucose
Measurement Following Use of Parenteral Maltose/Parenteral
Galactose/Oral Xylose-Containing Products. [Electronic Version]. Retrieved
June 30, 2009.
www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm154213.htm
.
2. U.S. Food and Drug Administration. Blood Glucose Meters, Getting the Most
Out of Your Meter. [Electronic Version]. Retrieved June 16, 2009:
www.fda.gov/MedicalDevices/Safety/AlertsandNotices/TipsandArticlesonDe
viceSafety/ucm109371.htm.
3. Larsson-Cohn U: Difference between capillary and venous blood glucose
during oral glucose tolerance tests. Scand J Clin Lab Invest 36:805-808,
1976.
4. Food & Drug Administration 2007. Draft Guidance for Industry and Staff.
Total Product Life Cycle for Portable Invasive Blood Glucose Monitoring
System. [Electronic Version]. Retrieved February 5, 2007:
www.fda.gov/cdrh/oivd/guidance/1603.pdf
.
5. Data on file.
6. American Diabetes Association. Standards of Medical Care, Diabetes Care
33 (Suppl. 1): S11-S61, 2010. [Electronic Version]. Retrieved January 11,
2010. http://care.diabetesjournals.org/content/33/Supplement_1/S11.full.
7. Good Laboratory Practices for Waived Testing Sites. [Electronic Version].
Retrieved July 14, 2008:
www.cdc.gov/mmwr/preview/mmwrhtml/rr5413a1.htm
.
TRUEresult
®
Quality Assurance / Quality Control Manual
63
To Previous Page
Loading...
